{"filing":{"accession_number":"0001193125-26-397219","cik":"0001607678","ticker":"VKTX","company_name":"Viking Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"vktx-20260922.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/vktx-20260922.htm"},"events":[{"id":34167,"run_id":31437,"accession_number":"0001193125-26-397219","anchor_item_number":"8.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Viking Therapeutics announced positive top-line results from a clinical maintenance study of its lead candidate VK2735, a GLP-1/GIP agonist. The press release discloses detailed efficacy and safety data from a Phase 2 maintenance study, including weight loss percentages, maintenance rates across dosing regimens, and adverse event profiles. This constitutes a material clinical trial result disclosure that would significantly affect investor assessment of the company's pipeline and commercial prospects for its obesity treatment candidate.","company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":37830,"accession_number":"0001193125-26-397219","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Viking Therapeutics announced positive top-line results from a clinical maintenance study of its lead candidate VK2735, a GLP-1/GIP agonist. The press release discloses detailed efficacy and safety data from a Phase 2 maintenance study, including weight loss percentages, maintenance rates across dosing regimens, and adverse event profiles. This constitutes a material clinical trial result disclosure that would significantly affect investor assessment of the company's pipeline and commercial prospects for its obesity treatment candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T11:07:40.507422+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37830,"accession_number":"0001193125-26-397219","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Viking Therapeutics announced positive top-line results from a clinical maintenance study of its lead candidate VK2735, a GLP-1/GIP agonist. The press release discloses detailed efficacy and safety data from a Phase 2 maintenance study, including weight loss percentages, maintenance rates across dosing regimens, and adverse event profiles. This constitutes a material clinical trial result disclosure that would significantly affect investor assessment of the company's pipeline and commercial prospects for its obesity treatment candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T11:07:40.507422+00:00","company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","filing_date":"2026-09-22"}]}